TORONTO, Aug. 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), acompany focused on developing patient-friendly blood-based biomarker tests forthe detection and staging of virtually any disease or medical condition, todayannounced that its co-founder and Chief Scientist Dr. C.C. Liew, has co-editeda newly published genomics reference book entitled Cardiovascular Genetics andGenomics for the Cardiologist. The text provides cardiologists with anoverview of cardiovascular genetics and genomics, which have been changing thefundamental understanding of cardiovascular disease and the practice ofcardiovascular medicine.
"We are very proud of our Chief Scientist and the inventor of our coretechnologies, Dr. C.C. Liew. This is not only a significant achievement forDr. Liew, but also an important and notable contribution to both the field ofdisease-specific genomics and the field of cardiovascular medicine," said K.Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews."Dr. Liew is truly a pioneer in disease-specific genomics and has earned aglobal reputation for his outstanding scientific contributions in thiscutting-edge area of healthscience."
Dr. Liew currently holds the positions of Visiting Professor of Medicineand Founding Director of the Cardiovascular Genome Unit at Brigham and Women'sHospital, Harvard Medical School, and Professor Emeritus at the University ofToronto. Genetics and Genomics for the Cardiologist is currently availablefrom the publisher, Blackwell Publishing Inc. (www.blackwellcardiology.com).
GeneNews is focused on the application of functional genomics to enableearly diagnosis and personalized therapeutic intervention based ondisease-specific biomarkers. The Company has developed a novel approach, theSentinel Principle(TM), to detect and stage virtually any disease or medicalcondition from a simple blood sample. GeneNews is currently applying theSentinel Principle(TM) in major areas with unmet clinical needs such ascancer, arthritis, cardiovascular disease and neurological disorders.GeneNews' first product in development, ColonSentry(TM), is a convenient andpatient-friendly blood-based biomarker test that can detect colon cancer. Formore information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect theCompany's current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein. Investors should consult the Company'songoing quarterly filings and annual reports for additional information onrisks and uncertainties relating to these forward-looking statements. Thereader is cautioned not to rely on these forward-looking statements. TheCompany disclaims any obligation to update these forward-looking statements.
SOURCE GeneNews Limited